Uniting innovators of transformative bioscience data and technology is a priority at the Earlham Institute.
EI Innovate is an annual engagement event that provides insight into the Earlham Institute’s research, exploring opportunities for innovation and collaboration. Specialising in agri-food, biotech, med-tech and public health, we have a wealth of experience collaborating with others to develop potential solutions to urgent industrial and societal challenges.
Director of Business Development
biomodal
If you’d like to learn more about duet multiomics solution +modC and how it could transform your research, reach out to Aziz.
Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.
The Aparicio lab at the British Columbia Cancer Research Centre (BCCRC) utilises 5-letter sequencing technology, duet multiomics solution +modC, to investigate ‘epigenetic rewiring’ in breast cancer cells.
Learn how simultaneous measurement of genetics and epigenetics with duet multiomics solution +modC enables the study of allele-specific methylation and how this can be used to understand the impact of epigenetic rejuvenation.
Review performance of duet multiomics solution +modC for the detection of genetic and epigenetic sequence data at base resolution when using formalin damaged DNA. Samples include formalin-compromised DNA standards (fcDNA) as well as DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of two colorectal cancer (CRC) patients.
Learn how duet multiomics solution +modC is transforming research efforts in early cancer detection, risk stratification, and disease monitoring by using liquid biopsy for profiling of cfDNA. This poster illustrates how capturing complete genetic and epigenetic information in one workflow, from a single low-volume DNA sample is more powerful for early disease detection than either alone.
The award-winning researcher behind next generation sequencing (NGS)
